array:23 [
  "pii" => "S0300289622000928"
  "issn" => "03002896"
  "doi" => "10.1016/j.arbres.2022.02.002"
  "estado" => "S300"
  "fechaPublicacion" => "2022-10-01"
  "aid" => "3023"
  "copyright" => "SEPAR"
  "copyrightAnyo" => "2022"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "edi"
  "cita" => "Arch Bronconeumol. 2022;58:685-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0300289622004525"
    "issn" => "03002896"
    "doi" => "10.1016/j.arbres.2022.05.015"
    "estado" => "S300"
    "fechaPublicacion" => "2022-10-01"
    "aid" => "3137"
    "copyright" => "SEPAR"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "edi"
    "cita" => "Arch Bronconeumol. 2022;58:687-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "Segmentectomy in Lung Cancer as a New Standard of Treatment&#58; Can Less Be More&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "687"
          "paginaFinal" => "688"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Jesus Isea de la Vi&#241;a, Gema Ram&#237;rez-Rodr&#237;guez, Bernardino Alc&#225;zar-Navarrete"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Jesus"
              "apellidos" => "Isea de la Vi&#241;a"
            ]
            1 => array:2 [
              "nombre" => "Gema"
              "apellidos" => "Ram&#237;rez-Rodr&#237;guez"
            ]
            2 => array:2 [
              "nombre" => "Bernardino"
              "apellidos" => "Alc&#225;zar-Navarrete"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289622004525?idApp=UINPBA00003Z"
    "url" => "/03002896/0000005800000010/v2_202302271800/S0300289622004525/v2_202302271800/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0300289622000102"
    "issn" => "03002896"
    "doi" => "10.1016/j.arbres.2021.12.013"
    "estado" => "S300"
    "fechaPublicacion" => "2022-10-01"
    "aid" => "2983"
    "copyright" => "SEPAR"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "edi"
    "cita" => "Arch Bronconeumol. 2022;58:681-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "Current Knowledge and Perspectives for Pharmacological Treatment in OSA"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "681"
          "paginaFinal" => "684"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1354
              "Ancho" => 2500
              "Tamanyo" => 261884
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">From conventional continuous positive airway pressure therapy to emerging targeted pharmacological approaches for OSA&#46; Abbreviations&#58; PAP&#58; positive airway pressure&#59; OSA&#58; obstructive sleep apnoea&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "S&#233;bastien Baillieul, Renaud Tamisier, Danny J&#46; Eckert, Jean-Louis P&#233;pin"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "S&#233;bastien"
              "apellidos" => "Baillieul"
            ]
            1 => array:2 [
              "nombre" => "Renaud"
              "apellidos" => "Tamisier"
            ]
            2 => array:2 [
              "nombre" => "Danny J&#46;"
              "apellidos" => "Eckert"
            ]
            3 => array:2 [
              "nombre" => "Jean-Louis"
              "apellidos" => "P&#233;pin"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289622000102?idApp=UINPBA00003Z"
    "url" => "/03002896/0000005800000010/v2_202302271800/S0300289622000102/v2_202302271800/en/main.assets"
  ]
  "en" => array:10 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
    "titulo" => "Pulmonary Hypertension in Interstitial Lung Disease"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "685"
        "paginaFinal" => "686"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Bruno Guedes Baldi, Rog&#233;rio Souza"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Bruno Guedes"
            "apellidos" => "Baldi"
            "email" => array:1 [
              0 => "bruno.baldi@hc.fm.usp.br"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Rog&#233;rio"
            "apellidos" => "Souza"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Divis&#227;o de Pneumologia&#44; Instituto do Cora&#231;&#227;o &#40;InCor&#41;&#44; Hospital das Clinicas HCFMUSP&#44; Faculdade de Medicina&#44; Universidade de S&#227;o Paulo&#44; S&#227;o Paulo&#44; Brazil"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Hospital do Cora&#231;&#227;o&#44; S&#227;o Paulo&#44; Brazil"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Patients with diverse interstitial lung diseases &#40;ILDs&#41; may develop pulmonary hypertension &#40;PH&#41; during follow-up&#44; most with a pre-capillary pattern at invasive hemodynamics&#44; being classified within groups 3 and 5 in the current classification of PH&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1&#44;2</span></a> Precapillary PH associated with ILD &#40;PH-ILD&#41; is currently defined as the presence of pulmonary vascular resistance &#40;PVR&#41; &#8805;3 WU associated with mean pulmonary arterial pressure &#40;mPAP&#41; &#62;20<span class="elsevierStyleHsp" style=""></span>mmHg and pulmonary artery wedge pressure &#8804;15<span class="elsevierStyleHsp" style=""></span>mmHg at rest as assessed by right heart catheterization &#40;RHC&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1&#44;3</span></a> The majority of PH-ILD is included in the group 3 and related to the parenchymal involvement&#44; such as observed in fibrotic idiopathic interstitial pneumonia &#40;IIP&#41;&#44; hypersensitivity pneumonitis and lymphangioleiomyomatosis&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1&#44;2&#44;4</span></a> However&#44; PH associated with sarcoidosis&#44; pulmonary Langerhans cell histiocytosis and metabolic disorders&#44; given the diversity of potential pathophysiological events that might be responsible for the development of PH&#44; are currently classified within the group 5&#44; with unclear and&#47;or multifactorial mechanisms&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1&#44;2&#44;5</span></a> Nevertheless&#44; hypoxic vasoconstriction&#44; remodeling of small pulmonary vessels&#44; destruction and obliteration of the microvasculature&#44; and upregulation of vascular modifying cytokines&#44;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">3</span></a> isolated or in combination&#44; represent some of the recognized mechanisms potentially involved in the pathogenesis of PH-ILD&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">PH determines significant morbidity and mortality in patients with ILD&#46; Most data of PH associated with fibrotic IIP were obtained from studies with idiopathic pulmonary fibrosis &#40;IPF&#41;&#44; and demonstrate that the prevalence of PH increases with advanced disease&#46; However&#44; the development of PH in IPF is multifactorial so that the severity of PH is not always correlated with the impairment of the parenchymal involvement<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a>&#59; some patients with mild disease may present PH&#44; which can be consistent with other groups of PH classification&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">3</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Therefore&#44; it is reasonable to screen PH in symptomatic patients with ILD&#46; However&#44; the most adequate method for screening PH-ILD is still unknown&#46; Different tools may be used to screen PH in patients with parenchymal lung diseases&#44; including peripheral oxygen saturation &#40;SpO<span class="elsevierStyleInf">2</span>&#41; at rest or exercise&#44; transthoracic doppler echocardiography&#44; six-minute walk test&#44; diffusing capacity for carbon monoxide &#40;DLCO&#41;&#44; whose reduction can be compared to the decline of lung volumes&#44; and assessment of the main pulmonary artery and aorta diameters on CT scan&#46; These screen methods have different sensitivities according to each ILD&#46;<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">3&#8211;5</span></a> RHC is the confirmatory diagnostic method of PH associated with ILD and should be considered mainly for those in which therapeutic interventions will be performed&#46;<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">2&#44;4&#44;5</span></a> It is important to emphasize that the presence of PH in a patient with ILD does not preclude the need exclude other causes of PH&#44; beside the parenchymal disease&#46; In this sense&#44; it is important to exclude the presence of left heart dysfunction and chronic thromboembolic disease&#46; Furthermore&#44; the main end-points to assess the response to therapeutic interventions in PH include dyspnea and quality of life scores&#44; six-minute walking distance&#44; decline in forced vital capacity &#40;FVC&#41; and in DLCO&#44; hospitalizations&#44; acute exacerbation&#44; death from any cause or lung transplantation&#44; and pulmonary hemodynamic parameters&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Several advances have been made in the approach to diseases in the area of pulmonary circulation&#44; but consistent innovations in the treatment of PH-ILD have only occurred very recently&#44; mostly in IIP&#44; with a main focus in IPF&#46;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">6</span></a> Systematic reviews and randomized clinical trials with different systemic pulmonary vasoactive drugs&#44; such as endothelin-receptor antagonists &#40;ambrisentan and bosentan&#41;&#44; phosphodiesterase-5 inhibitors &#40;sildenafil&#41; and riociguat&#44; had conflicting results and did not demonstrate robust benefits with some of them even determining harm effects in relevant clinical&#44; functional and pulmonary hemodynamic outcomes in patients with PH secondary to IIP&#46; The main mechanisms speculated for the lack of positive effects of such drugs are the worsening of pulmonary ventilation&#47;perfusion mismatch and gas exchange&#44; and the presence of left sided heart failure&#46;<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">7&#8211;11</span></a> For other ILDs&#44; data are still scarce and less robust&#46; A placebo-controlled trial demonstrated that bosentan improved pulmonary hemodynamics in patients with PH associated with sarcoidosis after 16 weeks&#44; with no benefits on the distance walked&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">12</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">In this scenario&#44; the use of inhaled vasodilators&#44; such as pulse nitric oxide &#40;NO&#41; and treprostinil&#44; a prostacyclin analogue&#44; could mitigate the worsening of ventilation&#47;perfusion mismatching through the pulmonary vasodilation of better ventilated areas&#46;<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">13&#44;14</span></a> Treatment with pulse NO for eight weeks in subjects with fibrotic ILD was safe&#44; well tolerated&#44; and showed improvement in physical activity and in oxygen saturation&#46;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">14</span></a> The benefit of inhaled treprostinil was demonstrated in patients with PH associated with diffuse parenchymal lung disease &#40;INCREASE trial&#41;&#44; with a significant improvement in the six-minute walking distance &#40;31<span class="elsevierStyleHsp" style=""></span>m&#41; after 16 weeks and a lower risk of clinical worsening&#44; without increase in adverse events&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">13</span></a> Additionally&#44; a post-hoc analysis demonstrated potential favorable effects of inhaled treprostinil on FVC&#44; mainly in those with IPF&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">15</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Although the role of oxygen supplementation on PH in patients with ILD was not clearly assessed&#44; hypoxaemia at rest&#44; during sleep or exercise should be treated&#46; Additionally&#44; it is essential to optimize treatment of the parenchymal component of the underlying ILD&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a> However&#44; the impact of antifibrotics on PH-ILD remains unknown&#46; Lung transplantation&#44; preferably bilateral&#44; remains the unique current option with impact on survival in patients with PH-ILD&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">3</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Therefore&#44; appropriate drug treatment of PH-ILD has not been established yet&#46; Despite the favorable perspectives with inhaled vasodilators&#44; several questions remain unknown&#46; It is essential to evaluate the impact of inhaled vasodilators on larger samples of patients with fibrotic ILD and on other causes of ILD&#44; such as sarcoidosis and cystic lung diseases&#46; Further research is warranted to address the role of inhaled vasodilators on exercise capacity&#44; functional variables and gas exchange in the long-term&#44; and also on mortality&#44; need of lung transplantation and hospitalizations&#46; The impact of combination therapy&#44; with vasodilators and antifibrotics&#44; in PH-ILD is unknow&#46; It is still not determined whether inhaled vasodilators have impact not only on vascular properties&#44; but also on parenchymal fibrosis&#46; Furthermore&#44; it is essential to identify the subgroups of patients&#44; according to severity of PH and the group of ILD&#44; that would benefit from the use of vasodilators&#44; and to assess other treatment modalities acting on other pathways regarding the potential pathogenesis of PH-ILD&#44; including attenuation of vascular remodeling&#46; Due to the high complexity of the issue and to many unanswered questions&#44; patients with PH-ILD should preferably be referred to experienced centers in PH and ILD&#44; especially if there is a prospect of specific therapy&#44; inclusion in clinical trials&#44; or lung transplantation&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:15 [
            0 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Haemodynamicdefinitions and updated clinical classification of pulmonary hypertension"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Simonneau"
                            1 => "D&#46; Montani"
                            2 => "D&#46;S&#46; Celermajer"
                            3 => "C&#46;P&#46; Denton"
                            4 => "M&#46;A&#46; Gatzoulis"
                            5 => "M&#46; Krowka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/13993003.01913-2018"
                      "Revista" => array:5 [
                        "tituloSerie" => "Eur Respir J"
                        "fecha" => "2019"
                        "volumen" => "53"
                        "paginaInicial" => "1801913"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30545968"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2015 ESC&#47;ERS guidelines for the diagnosis and treatment of pulmonary hypertension&#58; the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology &#40;ESC&#41; and the European Respiratory Society &#40;ERS&#41;&#58; endorsed by&#58; Association for European Paediatric and Congenital Cardiology &#40;AEPC&#41;&#44; International Society for Heart and Lung Transplantation &#40;ISHLT&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46; Galie"
                            1 => "M&#46; Humbert"
                            2 => "J&#46;L&#46; Vachiery"
                            3 => "S&#46; Gibbs"
                            4 => "I&#46; Lang"
                            5 => "A&#46; Torbicki"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/13993003.01032-2015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J"
                        "fecha" => "2015"
                        "volumen" => "46"
                        "paginaInicial" => "903"
                        "paginaFinal" => "975"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26318161"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia&#58; uncertainties&#44; challenges and opportunities"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46;E&#46; Girgis"
                            1 => "M&#46;M&#46; Hoeper"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.healun.2021.03.004"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Heart Lung Transplant"
                        "fecha" => "2021"
                        "volumen" => "40"
                        "paginaInicial" => "872"
                        "paginaFinal" => "881"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pulmonary hypertension in lymphangioleiomyomatosis&#58; prevalence&#44; severity and the role of carbon monoxide capacity as a screening method"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;S&#46;G&#46; Freitas"
                            1 => "B&#46;G&#46; Baldi"
                            2 => "C&#46; Jardim"
                            3 => "M&#46;S&#46; Araujo"
                            4 => "J&#46;B&#46; Sobral"
                            5 => "G&#46;I&#46; Heiden"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13023-017-0626-0"
                      "Revista" => array:5 [
                        "tituloSerie" => "Orphanet J Rare Dis"
                        "fecha" => "2017"
                        "volumen" => "12"
                        "paginaInicial" => "74"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28427470"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mechanisms of exercise limitation and prevalence of pulmonary hypertension in pulmonary Langerhans cell histiocytosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;I&#46; Heiden"
                            1 => "J&#46;B&#46; Sobral"
                            2 => "C&#46;S&#46;G&#46; Freitas"
                            3 => "A&#46;L&#46;P&#46; Albuquerque"
                            4 => "J&#46;M&#46; Salge"
                            5 => "R&#46;A&#46; Kairalla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.chest.2020.05.609"
                      "Revista" => array:5 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2020"
                        "volumen" => "158"
                        "paginaInicial" => "2440"
                        "paginaFinal" => "2448"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "World Pulmonary Hypertension Day&#58; reflections and planning"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;S&#46; Ota-Arakaki"
                            1 => "F&#46;T&#46;A&#46;F&#46; Campos"
                            2 => "R&#46; Souza"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.36416/1806-3756/e20210251"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Bras Pneumol"
                        "fecha" => "2021"
                        "volumen" => "47"
                        "paginaInicial" => "e20210251"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34287559"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis Official document of the Brazilian Thoracic Association based on the GRADE methodology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Baddini-Martinez"
                            1 => "J&#46; Ferreira"
                            2 => "S&#46; Tanni"
                            3 => "L&#46;R&#46; Alves"
                            4 => "B&#46;F&#46; Cabral Junior"
                            5 => "C&#46;R&#46;R&#46; Carvalho"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.36416/1806-3756/e20190423"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Bras Pneumol"
                        "fecha" => "2020"
                        "volumen" => "46"
                        "paginaInicial" => "e20190423"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32130337"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;J&#46; Corte"
                            1 => "G&#46;J&#46; Keir"
                            2 => "K&#46; Dimopoulos"
                            3 => "L&#46; Howard"
                            4 => "P&#46;A&#46; Corris"
                            5 => "L&#46; Parfitt"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201403-0446OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med"
                        "fecha" => "2014"
                        "volumen" => "190"
                        "paginaInicial" => "208"
                        "paginaFinal" => "217"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24937643"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of idiopathic pulmonary fibrosis with ambrisentan&#58; a parallel&#44; randomized trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Raghu"
                            1 => "J&#46; Behr"
                            2 => "K&#46;K&#46; Brown"
                            3 => "J&#46;J&#46; Egan"
                            4 => "S&#46;M&#46; Kawut"
                            5 => "K&#46;R&#46; Flaherty"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-158-9-201305070-00003"
                      "Revista" => array:5 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "2013"
                        "volumen" => "158"
                        "paginaInicial" => "641"
                        "paginaFinal" => "649"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension &#40;RISE-IIP&#58; a randomised&#44; placebo-controlled phase 2b study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;D&#46; Nathan"
                            1 => "J&#46; Behr"
                            2 => "H&#46;R&#46; Collard"
                            3 => "V&#46; Cottin"
                            4 => "M&#46;H&#46; Hoeper"
                            5 => "F&#46;M&#46; Martinez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2213-2600(19)30250-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Respir Med"
                        "fecha" => "2019"
                        "volumen" => "7"
                        "paginaInicial" => "780"
                        "paginaFinal" => "790"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31416769"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Idiopathic Pulmonary Fibrosis Clinical Research Network&#46; A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "D&#46;A&#46; Zisman"
                            1 => "M&#46; Schwarz"
                            2 => "K&#46;J&#46; Anstrom"
                            3 => "H&#46;R&#46; Collard"
                            4 => "K&#46;R&#46; Flaherty"
                            5 => "G&#46;W&#46; Hunninghake"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1002110"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2010"
                        "volumen" => "363"
                        "paginaInicial" => "620"
                        "paginaFinal" => "628"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20484178"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bosentan for sarcoidosis-associated pulmonary hypertension&#58; a double-blind placebo controlled randomized trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;P&#46; Baughman"
                            1 => "D&#46;A&#46; Culver"
                            2 => "F&#46;C&#46; Cordova"
                            3 => "M&#46; Padilla"
                            4 => "K&#46;F&#46; Gibson"
                            5 => "E&#46;E&#46; Lower"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1378/chest.13-1766"
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2014"
                        "volumen" => "145"
                        "paginaInicial" => "810"
                        "paginaFinal" => "817"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24177203"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Waxman"
                            1 => "R&#46; Restrepo-Jaramillo"
                            2 => "T&#46; Thenappan"
                            3 => "A&#46; Ravichandran"
                            4 => "P&#46; Engel"
                            5 => "A&#46; Bajwa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa2008470"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2021"
                        "volumen" => "384"
                        "paginaInicial" => "325"
                        "paginaFinal" => "334"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33440084"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized&#44; double-blind&#44; placebo-controlled study of pulsed&#44; inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;D&#46; Nathan"
                            1 => "K&#46;R&#46; Flaherty"
                            2 => "M&#46;K&#46; Glassberg"
                            3 => "G&#46; Raghu"
                            4 => "J&#46; Swigris"
                            5 => "R&#46; Alvarez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.chest.2020.02.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2020"
                        "volumen" => "158"
                        "paginaInicial" => "637"
                        "paginaFinal" => "645"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32092321"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonar hypertension&#58; a post-hoc analysis of the INCREASE study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;D&#46; Nathan"
                            1 => "A&#46; Waxman"
                            2 => "S&#46; Rajagopal"
                            3 => "A&#46; Case"
                            4 => "S&#46; Johri"
                            5 => "H&#46; DuBrock"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2213-2600(21)00165-X"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Respir Med"
                        "fecha" => "2021"
                        "volumen" => "9"
                        "paginaInicial" => "1266"
                        "paginaFinal" => "1274"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34214475"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/03002896/0000005800000010/v2_202302271800/S0300289622000928/v2_202302271800/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "93561"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Editorials"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/03002896/0000005800000010/v2_202302271800/S0300289622000928/v2_202302271800/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289622000928?idApp=UINPBA00003Z"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Editorial
Pulmonary Hypertension in Interstitial Lung Disease
Bruno Guedes Baldia,b,
Corresponding author
bruno.baldi@hc.fm.usp.br

Corresponding author.
, Rogério Souzaa
a Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
b Hospital do Coração, São Paulo, Brazil
Read
5652
Times
was read the article
1478
Total PDF
4174
Total HTML
Share statistics
 array:23 [
  "pii" => "S0300289622000928"
  "issn" => "03002896"
  "doi" => "10.1016/j.arbres.2022.02.002"
  "estado" => "S300"
  "fechaPublicacion" => "2022-10-01"
  "aid" => "3023"
  "copyright" => "SEPAR"
  "copyrightAnyo" => "2022"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "edi"
  "cita" => "Arch Bronconeumol. 2022;58:685-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0300289622004525"
    "issn" => "03002896"
    "doi" => "10.1016/j.arbres.2022.05.015"
    "estado" => "S300"
    "fechaPublicacion" => "2022-10-01"
    "aid" => "3137"
    "copyright" => "SEPAR"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "edi"
    "cita" => "Arch Bronconeumol. 2022;58:687-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "Segmentectomy in Lung Cancer as a New Standard of Treatment&#58; Can Less Be More&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "687"
          "paginaFinal" => "688"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Jesus Isea de la Vi&#241;a, Gema Ram&#237;rez-Rodr&#237;guez, Bernardino Alc&#225;zar-Navarrete"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Jesus"
              "apellidos" => "Isea de la Vi&#241;a"
            ]
            1 => array:2 [
              "nombre" => "Gema"
              "apellidos" => "Ram&#237;rez-Rodr&#237;guez"
            ]
            2 => array:2 [
              "nombre" => "Bernardino"
              "apellidos" => "Alc&#225;zar-Navarrete"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289622004525?idApp=UINPBA00003Z"
    "url" => "/03002896/0000005800000010/v2_202302271800/S0300289622004525/v2_202302271800/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0300289622000102"
    "issn" => "03002896"
    "doi" => "10.1016/j.arbres.2021.12.013"
    "estado" => "S300"
    "fechaPublicacion" => "2022-10-01"
    "aid" => "2983"
    "copyright" => "SEPAR"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "edi"
    "cita" => "Arch Bronconeumol. 2022;58:681-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "Current Knowledge and Perspectives for Pharmacological Treatment in OSA"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "681"
          "paginaFinal" => "684"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1354
              "Ancho" => 2500
              "Tamanyo" => 261884
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">From conventional continuous positive airway pressure therapy to emerging targeted pharmacological approaches for OSA&#46; Abbreviations&#58; PAP&#58; positive airway pressure&#59; OSA&#58; obstructive sleep apnoea&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "S&#233;bastien Baillieul, Renaud Tamisier, Danny J&#46; Eckert, Jean-Louis P&#233;pin"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "S&#233;bastien"
              "apellidos" => "Baillieul"
            ]
            1 => array:2 [
              "nombre" => "Renaud"
              "apellidos" => "Tamisier"
            ]
            2 => array:2 [
              "nombre" => "Danny J&#46;"
              "apellidos" => "Eckert"
            ]
            3 => array:2 [
              "nombre" => "Jean-Louis"
              "apellidos" => "P&#233;pin"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289622000102?idApp=UINPBA00003Z"
    "url" => "/03002896/0000005800000010/v2_202302271800/S0300289622000102/v2_202302271800/en/main.assets"
  ]
  "en" => array:10 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
    "titulo" => "Pulmonary Hypertension in Interstitial Lung Disease"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "685"
        "paginaFinal" => "686"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Bruno Guedes Baldi, Rog&#233;rio Souza"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Bruno Guedes"
            "apellidos" => "Baldi"
            "email" => array:1 [
              0 => "bruno.baldi@hc.fm.usp.br"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Rog&#233;rio"
            "apellidos" => "Souza"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Divis&#227;o de Pneumologia&#44; Instituto do Cora&#231;&#227;o &#40;InCor&#41;&#44; Hospital das Clinicas HCFMUSP&#44; Faculdade de Medicina&#44; Universidade de S&#227;o Paulo&#44; S&#227;o Paulo&#44; Brazil"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Hospital do Cora&#231;&#227;o&#44; S&#227;o Paulo&#44; Brazil"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Patients with diverse interstitial lung diseases &#40;ILDs&#41; may develop pulmonary hypertension &#40;PH&#41; during follow-up&#44; most with a pre-capillary pattern at invasive hemodynamics&#44; being classified within groups 3 and 5 in the current classification of PH&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1&#44;2</span></a> Precapillary PH associated with ILD &#40;PH-ILD&#41; is currently defined as the presence of pulmonary vascular resistance &#40;PVR&#41; &#8805;3 WU associated with mean pulmonary arterial pressure &#40;mPAP&#41; &#62;20<span class="elsevierStyleHsp" style=""></span>mmHg and pulmonary artery wedge pressure &#8804;15<span class="elsevierStyleHsp" style=""></span>mmHg at rest as assessed by right heart catheterization &#40;RHC&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1&#44;3</span></a> The majority of PH-ILD is included in the group 3 and related to the parenchymal involvement&#44; such as observed in fibrotic idiopathic interstitial pneumonia &#40;IIP&#41;&#44; hypersensitivity pneumonitis and lymphangioleiomyomatosis&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1&#44;2&#44;4</span></a> However&#44; PH associated with sarcoidosis&#44; pulmonary Langerhans cell histiocytosis and metabolic disorders&#44; given the diversity of potential pathophysiological events that might be responsible for the development of PH&#44; are currently classified within the group 5&#44; with unclear and&#47;or multifactorial mechanisms&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1&#44;2&#44;5</span></a> Nevertheless&#44; hypoxic vasoconstriction&#44; remodeling of small pulmonary vessels&#44; destruction and obliteration of the microvasculature&#44; and upregulation of vascular modifying cytokines&#44;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">3</span></a> isolated or in combination&#44; represent some of the recognized mechanisms potentially involved in the pathogenesis of PH-ILD&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">PH determines significant morbidity and mortality in patients with ILD&#46; Most data of PH associated with fibrotic IIP were obtained from studies with idiopathic pulmonary fibrosis &#40;IPF&#41;&#44; and demonstrate that the prevalence of PH increases with advanced disease&#46; However&#44; the development of PH in IPF is multifactorial so that the severity of PH is not always correlated with the impairment of the parenchymal involvement<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a>&#59; some patients with mild disease may present PH&#44; which can be consistent with other groups of PH classification&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">3</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Therefore&#44; it is reasonable to screen PH in symptomatic patients with ILD&#46; However&#44; the most adequate method for screening PH-ILD is still unknown&#46; Different tools may be used to screen PH in patients with parenchymal lung diseases&#44; including peripheral oxygen saturation &#40;SpO<span class="elsevierStyleInf">2</span>&#41; at rest or exercise&#44; transthoracic doppler echocardiography&#44; six-minute walk test&#44; diffusing capacity for carbon monoxide &#40;DLCO&#41;&#44; whose reduction can be compared to the decline of lung volumes&#44; and assessment of the main pulmonary artery and aorta diameters on CT scan&#46; These screen methods have different sensitivities according to each ILD&#46;<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">3&#8211;5</span></a> RHC is the confirmatory diagnostic method of PH associated with ILD and should be considered mainly for those in which therapeutic interventions will be performed&#46;<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">2&#44;4&#44;5</span></a> It is important to emphasize that the presence of PH in a patient with ILD does not preclude the need exclude other causes of PH&#44; beside the parenchymal disease&#46; In this sense&#44; it is important to exclude the presence of left heart dysfunction and chronic thromboembolic disease&#46; Furthermore&#44; the main end-points to assess the response to therapeutic interventions in PH include dyspnea and quality of life scores&#44; six-minute walking distance&#44; decline in forced vital capacity &#40;FVC&#41; and in DLCO&#44; hospitalizations&#44; acute exacerbation&#44; death from any cause or lung transplantation&#44; and pulmonary hemodynamic parameters&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Several advances have been made in the approach to diseases in the area of pulmonary circulation&#44; but consistent innovations in the treatment of PH-ILD have only occurred very recently&#44; mostly in IIP&#44; with a main focus in IPF&#46;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">6</span></a> Systematic reviews and randomized clinical trials with different systemic pulmonary vasoactive drugs&#44; such as endothelin-receptor antagonists &#40;ambrisentan and bosentan&#41;&#44; phosphodiesterase-5 inhibitors &#40;sildenafil&#41; and riociguat&#44; had conflicting results and did not demonstrate robust benefits with some of them even determining harm effects in relevant clinical&#44; functional and pulmonary hemodynamic outcomes in patients with PH secondary to IIP&#46; The main mechanisms speculated for the lack of positive effects of such drugs are the worsening of pulmonary ventilation&#47;perfusion mismatch and gas exchange&#44; and the presence of left sided heart failure&#46;<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">7&#8211;11</span></a> For other ILDs&#44; data are still scarce and less robust&#46; A placebo-controlled trial demonstrated that bosentan improved pulmonary hemodynamics in patients with PH associated with sarcoidosis after 16 weeks&#44; with no benefits on the distance walked&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">12</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">In this scenario&#44; the use of inhaled vasodilators&#44; such as pulse nitric oxide &#40;NO&#41; and treprostinil&#44; a prostacyclin analogue&#44; could mitigate the worsening of ventilation&#47;perfusion mismatching through the pulmonary vasodilation of better ventilated areas&#46;<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">13&#44;14</span></a> Treatment with pulse NO for eight weeks in subjects with fibrotic ILD was safe&#44; well tolerated&#44; and showed improvement in physical activity and in oxygen saturation&#46;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">14</span></a> The benefit of inhaled treprostinil was demonstrated in patients with PH associated with diffuse parenchymal lung disease &#40;INCREASE trial&#41;&#44; with a significant improvement in the six-minute walking distance &#40;31<span class="elsevierStyleHsp" style=""></span>m&#41; after 16 weeks and a lower risk of clinical worsening&#44; without increase in adverse events&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">13</span></a> Additionally&#44; a post-hoc analysis demonstrated potential favorable effects of inhaled treprostinil on FVC&#44; mainly in those with IPF&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">15</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Although the role of oxygen supplementation on PH in patients with ILD was not clearly assessed&#44; hypoxaemia at rest&#44; during sleep or exercise should be treated&#46; Additionally&#44; it is essential to optimize treatment of the parenchymal component of the underlying ILD&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a> However&#44; the impact of antifibrotics on PH-ILD remains unknown&#46; Lung transplantation&#44; preferably bilateral&#44; remains the unique current option with impact on survival in patients with PH-ILD&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">3</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Therefore&#44; appropriate drug treatment of PH-ILD has not been established yet&#46; Despite the favorable perspectives with inhaled vasodilators&#44; several questions remain unknown&#46; It is essential to evaluate the impact of inhaled vasodilators on larger samples of patients with fibrotic ILD and on other causes of ILD&#44; such as sarcoidosis and cystic lung diseases&#46; Further research is warranted to address the role of inhaled vasodilators on exercise capacity&#44; functional variables and gas exchange in the long-term&#44; and also on mortality&#44; need of lung transplantation and hospitalizations&#46; The impact of combination therapy&#44; with vasodilators and antifibrotics&#44; in PH-ILD is unknow&#46; It is still not determined whether inhaled vasodilators have impact not only on vascular properties&#44; but also on parenchymal fibrosis&#46; Furthermore&#44; it is essential to identify the subgroups of patients&#44; according to severity of PH and the group of ILD&#44; that would benefit from the use of vasodilators&#44; and to assess other treatment modalities acting on other pathways regarding the potential pathogenesis of PH-ILD&#44; including attenuation of vascular remodeling&#46; Due to the high complexity of the issue and to many unanswered questions&#44; patients with PH-ILD should preferably be referred to experienced centers in PH and ILD&#44; especially if there is a prospect of specific therapy&#44; inclusion in clinical trials&#44; or lung transplantation&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:15 [
            0 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Haemodynamicdefinitions and updated clinical classification of pulmonary hypertension"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Simonneau"
                            1 => "D&#46; Montani"
                            2 => "D&#46;S&#46; Celermajer"
                            3 => "C&#46;P&#46; Denton"
                            4 => "M&#46;A&#46; Gatzoulis"
                            5 => "M&#46; Krowka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/13993003.01913-2018"
                      "Revista" => array:5 [
                        "tituloSerie" => "Eur Respir J"
                        "fecha" => "2019"
                        "volumen" => "53"
                        "paginaInicial" => "1801913"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30545968"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2015 ESC&#47;ERS guidelines for the diagnosis and treatment of pulmonary hypertension&#58; the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology &#40;ESC&#41; and the European Respiratory Society &#40;ERS&#41;&#58; endorsed by&#58; Association for European Paediatric and Congenital Cardiology &#40;AEPC&#41;&#44; International Society for Heart and Lung Transplantation &#40;ISHLT&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46; Galie"
                            1 => "M&#46; Humbert"
                            2 => "J&#46;L&#46; Vachiery"
                            3 => "S&#46; Gibbs"
                            4 => "I&#46; Lang"
                            5 => "A&#46; Torbicki"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/13993003.01032-2015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J"
                        "fecha" => "2015"
                        "volumen" => "46"
                        "paginaInicial" => "903"
                        "paginaFinal" => "975"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26318161"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia&#58; uncertainties&#44; challenges and opportunities"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46;E&#46; Girgis"
                            1 => "M&#46;M&#46; Hoeper"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.healun.2021.03.004"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Heart Lung Transplant"
                        "fecha" => "2021"
                        "volumen" => "40"
                        "paginaInicial" => "872"
                        "paginaFinal" => "881"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pulmonary hypertension in lymphangioleiomyomatosis&#58; prevalence&#44; severity and the role of carbon monoxide capacity as a screening method"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;S&#46;G&#46; Freitas"
                            1 => "B&#46;G&#46; Baldi"
                            2 => "C&#46; Jardim"
                            3 => "M&#46;S&#46; Araujo"
                            4 => "J&#46;B&#46; Sobral"
                            5 => "G&#46;I&#46; Heiden"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13023-017-0626-0"
                      "Revista" => array:5 [
                        "tituloSerie" => "Orphanet J Rare Dis"
                        "fecha" => "2017"
                        "volumen" => "12"
                        "paginaInicial" => "74"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28427470"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mechanisms of exercise limitation and prevalence of pulmonary hypertension in pulmonary Langerhans cell histiocytosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;I&#46; Heiden"
                            1 => "J&#46;B&#46; Sobral"
                            2 => "C&#46;S&#46;G&#46; Freitas"
                            3 => "A&#46;L&#46;P&#46; Albuquerque"
                            4 => "J&#46;M&#46; Salge"
                            5 => "R&#46;A&#46; Kairalla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.chest.2020.05.609"
                      "Revista" => array:5 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2020"
                        "volumen" => "158"
                        "paginaInicial" => "2440"
                        "paginaFinal" => "2448"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "World Pulmonary Hypertension Day&#58; reflections and planning"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;S&#46; Ota-Arakaki"
                            1 => "F&#46;T&#46;A&#46;F&#46; Campos"
                            2 => "R&#46; Souza"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.36416/1806-3756/e20210251"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Bras Pneumol"
                        "fecha" => "2021"
                        "volumen" => "47"
                        "paginaInicial" => "e20210251"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34287559"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis Official document of the Brazilian Thoracic Association based on the GRADE methodology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Baddini-Martinez"
                            1 => "J&#46; Ferreira"
                            2 => "S&#46; Tanni"
                            3 => "L&#46;R&#46; Alves"
                            4 => "B&#46;F&#46; Cabral Junior"
                            5 => "C&#46;R&#46;R&#46; Carvalho"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.36416/1806-3756/e20190423"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Bras Pneumol"
                        "fecha" => "2020"
                        "volumen" => "46"
                        "paginaInicial" => "e20190423"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32130337"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;J&#46; Corte"
                            1 => "G&#46;J&#46; Keir"
                            2 => "K&#46; Dimopoulos"
                            3 => "L&#46; Howard"
                            4 => "P&#46;A&#46; Corris"
                            5 => "L&#46; Parfitt"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/rccm.201403-0446OC"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med"
                        "fecha" => "2014"
                        "volumen" => "190"
                        "paginaInicial" => "208"
                        "paginaFinal" => "217"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24937643"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of idiopathic pulmonary fibrosis with ambrisentan&#58; a parallel&#44; randomized trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Raghu"
                            1 => "J&#46; Behr"
                            2 => "K&#46;K&#46; Brown"
                            3 => "J&#46;J&#46; Egan"
                            4 => "S&#46;M&#46; Kawut"
                            5 => "K&#46;R&#46; Flaherty"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-158-9-201305070-00003"
                      "Revista" => array:5 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "2013"
                        "volumen" => "158"
                        "paginaInicial" => "641"
                        "paginaFinal" => "649"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension &#40;RISE-IIP&#58; a randomised&#44; placebo-controlled phase 2b study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;D&#46; Nathan"
                            1 => "J&#46; Behr"
                            2 => "H&#46;R&#46; Collard"
                            3 => "V&#46; Cottin"
                            4 => "M&#46;H&#46; Hoeper"
                            5 => "F&#46;M&#46; Martinez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2213-2600(19)30250-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Respir Med"
                        "fecha" => "2019"
                        "volumen" => "7"
                        "paginaInicial" => "780"
                        "paginaFinal" => "790"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31416769"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Idiopathic Pulmonary Fibrosis Clinical Research Network&#46; A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "D&#46;A&#46; Zisman"
                            1 => "M&#46; Schwarz"
                            2 => "K&#46;J&#46; Anstrom"
                            3 => "H&#46;R&#46; Collard"
                            4 => "K&#46;R&#46; Flaherty"
                            5 => "G&#46;W&#46; Hunninghake"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1002110"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2010"
                        "volumen" => "363"
                        "paginaInicial" => "620"
                        "paginaFinal" => "628"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20484178"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bosentan for sarcoidosis-associated pulmonary hypertension&#58; a double-blind placebo controlled randomized trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;P&#46; Baughman"
                            1 => "D&#46;A&#46; Culver"
                            2 => "F&#46;C&#46; Cordova"
                            3 => "M&#46; Padilla"
                            4 => "K&#46;F&#46; Gibson"
                            5 => "E&#46;E&#46; Lower"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1378/chest.13-1766"
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2014"
                        "volumen" => "145"
                        "paginaInicial" => "810"
                        "paginaFinal" => "817"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24177203"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Waxman"
                            1 => "R&#46; Restrepo-Jaramillo"
                            2 => "T&#46; Thenappan"
                            3 => "A&#46; Ravichandran"
                            4 => "P&#46; Engel"
                            5 => "A&#46; Bajwa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa2008470"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2021"
                        "volumen" => "384"
                        "paginaInicial" => "325"
                        "paginaFinal" => "334"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33440084"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized&#44; double-blind&#44; placebo-controlled study of pulsed&#44; inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;D&#46; Nathan"
                            1 => "K&#46;R&#46; Flaherty"
                            2 => "M&#46;K&#46; Glassberg"
                            3 => "G&#46; Raghu"
                            4 => "J&#46; Swigris"
                            5 => "R&#46; Alvarez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.chest.2020.02.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2020"
                        "volumen" => "158"
                        "paginaInicial" => "637"
                        "paginaFinal" => "645"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32092321"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonar hypertension&#58; a post-hoc analysis of the INCREASE study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;D&#46; Nathan"
                            1 => "A&#46; Waxman"
                            2 => "S&#46; Rajagopal"
                            3 => "A&#46; Case"
                            4 => "S&#46; Johri"
                            5 => "H&#46; DuBrock"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2213-2600(21)00165-X"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Respir Med"
                        "fecha" => "2021"
                        "volumen" => "9"
                        "paginaInicial" => "1266"
                        "paginaFinal" => "1274"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34214475"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/03002896/0000005800000010/v2_202302271800/S0300289622000928/v2_202302271800/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "93561"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Editorials"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/03002896/0000005800000010/v2_202302271800/S0300289622000928/v2_202302271800/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289622000928?idApp=UINPBA00003Z"
]
Article information
ISSN: 03002896
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 11 6 17
2024 October 93 43 136
2024 September 100 26 126
2024 August 108 37 145
2024 July 122 33 155
2024 June 134 32 166
2024 May 109 43 152
2024 April 107 36 143
2024 March 94 17 111
2024 February 102 33 135
2024 January 93 35 128
2023 December 141 35 176
2023 November 107 27 134
2023 October 189 49 238
2023 September 153 47 200
2023 August 150 38 188
2023 July 168 50 218
2023 June 152 28 180
2023 May 154 33 187
2023 April 141 53 194
2023 March 183 106 289
2023 February 173 72 245
2023 January 132 65 197
2022 December 195 61 256
2022 November 256 124 380
2022 October 776 322 1098
2022 September 6 4 10
2022 August 2 2 4
2022 June 9 8 17
2022 May 3 0 3
2022 April 1 2 3
2022 March 10 11 21
Show all

Follow this link to access the full text of the article

Archivos de Bronconeumología

Are you a health professional able to prescribe or dispense drugs?